First National Bank of Hutchinson Has $1.01 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

First National Bank of Hutchinson grew its stake in Zoetis Inc. (NYSE:ZTS) by 2.3% in the fourth quarter, HoldingsChannel reports. The fund owned 6,170 shares of the company’s stock after acquiring an additional 137 shares during the period. First National Bank of Hutchinson’s holdings in Zoetis were worth $1,005,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the stock. Callahan Advisors LLC raised its position in Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after purchasing an additional 6,221 shares during the last quarter. CIBC Asset Management Inc raised its position in shares of Zoetis by 24.1% during the fourth quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after acquiring an additional 46,050 shares during the last quarter. Pensionfund Sabic boosted its holdings in Zoetis by 55.6% in the fourth quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after acquiring an additional 4,000 shares during the last quarter. PFW Advisors LLC acquired a new stake in Zoetis in the fourth quarter worth about $1,764,000. Finally, Alberta Investment Management Corp lifted its position in Zoetis by 2,050.0% during the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock valued at $4,904,000 after purchasing an additional 28,700 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ZTS shares. Piper Sandler raised their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. UBS Group started coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. Finally, Morgan Stanley cut their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $215.90.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total transaction of $55,420.00. Following the completion of the sale, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,862 shares of company stock worth $312,254. 0.16% of the stock is owned by insiders.

Zoetis Trading Down 0.4 %

Zoetis stock opened at $163.76 on Thursday. The stock has a 50-day simple moving average of $166.81 and a 200 day simple moving average of $175.75. The stock has a market capitalization of $73.33 billion, a P/E ratio of 29.94, a PEG ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.22%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.